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Background
Published data from various regions evidenced that the
administration of Etanercept (ET) restored auxological
retardation attributed to the process of the chronic joint
inflammation.
Aim
To assess the impact of ET on growth pattern in Greek
JIA patients who had a resistant poly- or an oligoarthri-
tis. Methods: Data of 24 JIA patients (F:M 19:5, 20/24
with a polyarthritis) who had received ET at a median
age of 6.7 yrs (1.9-14.5 yrs) escorted by their auxological
parameters were collected. Standard Deviation Scores
f o rH e i g h t( H S D S )a n dB o d yM a s sI n d e x( B M I S D S )
were calculated according to sex- and age- matched per-
centiles of the healthy Greek population, 2 and 1 yrs
pre-ET treatment, and 1 and 2 yrs thereafter. Growth
velocity was defined as the change in Height SDS
(ΔHSDS) and in BMI (ΔBMISDS) and compared to the
time of ET initiation (baseline).
Results
At baseline 16/24 pts had a growth retardation (median
ΔHSDS –0.56); 11/16 showed a significant increase 1yr
post-treatment (ΔHSDS +0.29, p<0.001) which did not
further increase (2nd yr: ΔHSDS +0.15). Similarly, at
baseline, BMI was retarded in 14/24 pts (median
ΔBMISDS-0.6); in 10/14, BMI increased 1 and 2 yrs
post-ET (ΔBMISDS +0.31, +0.12 respectively, p<0.001)
and remained stable thereafter. Growth and BMI
improvements were not associated either with age of ET
initiation, or gender, or presence of ANA, or disease
duration, or JIA course or MDVAS.
Conclusion
ET treatment can restore the linear growth and BMI of
JIA patients irrespectively of their demographic or clinical
profile.
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